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Abstract
Duchenne muscular dystrophy (DMD) is a progressive and fatal disease of muscle wasting caused by loss of the cytoskeletal
protein dystrophin. In the heart, DMD results in progressive cardiomyopathy and dilation of the left ventricle through
mechanisms that are not fully understood. Previous reports have shown that loss of dystrophin causes sarcolemmal
instability and reduced mechanical compliance of isolated cardiac myocytes. To expand upon these findings, here we have
subjected the left ventricles of dystrophin-deficient mdx hearts to mechanical stretch. Unexpectedly, isolated mdx hearts
showed increased left ventricular (LV) compliance compared to controls during stretch as LV volume was increased above
normal end diastolic volume. During LV chamber distention, sarcomere lengths increased similarly in mdx and WT hearts
despite greater excursions in volume of mdx hearts. This suggests that the mechanical properties of the intact heart cannot
be modeled as a simple extrapolation of findings in single cardiac myocytes. To explain these findings, a model is proposed
in which disruption of the dystrophin-glycoprotein complex perturbs cell-extracellular matrix contacts and promotes the
apparent slippage of myocytes past each other during LV distension. In comparison, similar increases in LV compliance were
obtained in isolated hearts from b-sarcoglycan-null and laminin-a2 mutant mice, but not in dysferlin-null mice, suggesting
that increased whole-organ compliance in mdx mice is a specific effect of disrupted cell-extracellular matrix contacts and
not a general consequence of cardiomyopathy via membrane defect processes. Collectively, these findings suggest a novel
and cell-death independent mechanism for the progressive pathological LV dilation that occurs in DMD.
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Introduction
Duchenne muscular dystrophy (DMD) is an inherited disease of
progressive muscle wasting and is the most common form of
muscular dystrophy, affecting 1 in 3500 males [1]. The DMD gene
resides on the short arm of the X chromosome and encodes the
protein dystrophin [2,3,4]. Dystrophin is a 427 kDa cytoskeletal
protein and is a member of the dystrophin-glycoprotein complex
(DGC) in striated muscles [2,5,6]. The DGC is a multimeric
protein assembly that spans the sarcolemma, tethering the
extracellular matrix to the cytoskeletal architecture of the cell
[7]. Dystrophin is a cytoplasmic component of the DGC and plays
a crucial role in this trans-sarcolemma linkage, binding cytoplas-
mic c-actin at its N-terminus and the membrane glycoprotein b-
dystroglycan at its C-terminus [8,9,10]. The DGC protein a-
dystroglycan interacts with the extracellular matrix by binding
laminin in a glycosylation dependent manner [7,11]. In the
absence of dystrophin, the mechanical rigors of muscle contraction
are damaging to the sarcolemma. This mechanical instability has
been observed in dystrophin-deficient skeletal muscle, which is
highly susceptible to lengthening contraction-induced sarcolemmal
damage and necrotic cell death [12,13]. Previously, we and others
have demonstrated similar mechanical instability in isolated single
cardiac myocytes, by showing that loss of dystrophin causes the
formation of ‘‘micro-tears’’ in the sarcolemma during passive
mechanical distension of myocyte [14,15,16]. Recently, loss of
dystrophin has also been shown to increase susceptibility to
mechanical injury in multicellular cardiac trabecular preparations
[17]. These sarcolemmal disruptions result in increased single-cell
stiffness with eventual hypercontracture and cell death during
physiological stretch due to unregulated influx of extracellular
calcium [15,16].
Clinically, DMD is characterized by skeletal muscle weakness
and wasting. DMD presents early in life and is rapidly progressive,
resulting in loss of ambulation at approximately 10 years of age
and premature death in the early twenties [18,19,20,21,22].
Progressive cardiac dysfunction is a significant component of
DMD which has been observed since the very first descriptions of
the disease [21,23]. Subclinical cardiac involvement is present in
the majority of DMD patients in the first decade, the severity of
which may be masked by significant skeletal muscle dysfunction
[21,24,25]. In the later stages of DMD, nearly all patients show
clinically significant cardiac muscle disease [26,27]. Structurally,
the cardiomyopathy of DMD is characterized by fibrosis and
progressive dilation of the left ventricle (LV), leading to dilated
cardiomyopathy (DCM) [27,28]. This frequently progresses to
heart failure, which is the primary cause of death in at least 20% of
DMD patients [21,26].
There are significant gaps in knowledge regarding the
progression of cardiac involvement in DMD. Increased myocyte
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myocytes may cause remodeling of LV dimensions early in DMD
[15]. At present, how dystrophin deficiency causes LV dilation as
the disease progresses is unclear. Previous findings regarding the
progression of DCM in the non-dystrophic heart suggest that
progressive LV dilation may involve myocyte loss, fibrosis,
hypertrophy, and myocyte slippage [29,30,31,32,33,34,35]. The
degree to which these processes contribute to cardiac dysfunction
and dilation in DMD is currently unknown.
In order to build on previous findings in single cardiac myocytes
and to gain new mechanistic understanding of the effects of
mechanical stress on the dystrophic heart, we tested the hypothesis
that isolated dystrophin-deficient hearts have reduced organ level
compliance and increased susceptibility to mechanical damage.
Using a modified ex vivo isolated heart preparation, results show,
unexpectedly, that isolated mdx hearts have increased whole-
organ compliance compared to normal hearts and tolerate
considerable LV chamber distension without showing evidence
of myocyte damage. To provide further mechanistic insight, we
tested other genetic models of dystrophy in which either the DGC
or native membrane repair apparatus were disrupted. We found
that defective organ level compliance was evident only when the
DGC or its extracellular binding partner laminin were disrupted
but not in hearts lacking the membrane repair protein dysferlin.
Collectively, these results provide evidence that disruption of the
DGC predisposes the LV to dilation via apparent myocyte
slippage, a novel and cell death-independent mechanism for the
progressive LV dilation observed in DMD.
Results
Previously, we have shown that the sarcolemma of single,
membrane intact, mdx cardiac myocytes is highly susceptible to
passive stretch-induced injury leading to increased stiffness,
membrane permeability, aberrant extracellular calcium influx,
and myocyte death [15]. To expand upon these findings and
determine how single-cell mechanics manifest at the whole-organ
level, the effects of mechanical stretch on the LV chamber of WT
and mdx hearts were determined (Figure 1).
Mechanical compliance of intact, beating mdx hearts
To determine whole-organ cardiac compliance, wild-type (WT,
C57BL/10SnJ) and mdx hearts were isolated, perfused, and
subjected to mechanical stretch using a water filled plastic balloon
placed within the LV chamber. WT and mdx mice used in this
study were of similar age (6560.9 vs. 6761.8 days, n=14–16,
P.0.05), had similar body weights (27.160.4 vs. 27.460.9 grams,
n=14–16, P.0.05) and heart weights (176.4 mg65.4 vs.
158.8610.3 milligrams, n=5, P.0.05). Miniature plastic balloons
were first inflated and set at standard physiological LV end
diastolic pressure (LVEDP) of 6–8 mmHg [15,36]. Baseline LV
hemodynamic performance of mdx and WT hearts was similar
(Table S1). In order to estimate the LV volume of isolated hearts at
standard LVEDP, the volume required to reach LVEDP of
8 mmHg was recorded (Vinit, Figure 1c). In agreement with
previously published findings, we found that mdx hearts have
reduced LV volumes at normal LVEDP [15]. To assess whole-
organ compliance in isolated hearts, 15 mL was added to the
balloon in the LV chamber in 1 mL increments while simulta-
neously recording LV pressure. Unexpectedly, as volume was
added above Vinit mdx hearts showed a blunted increase in
LVEDP, indicating an increase in whole-organ compliance
compared to WT hearts (representative tracings shown in
Figure 1a, b). This blunted increase in LVEDP as LV volume
increased above Vinit is quantified in Figure 1d, showing significant
main effects of strain, volume and an interaction of the two. To
account for differences in Vinit between WT and mdx hearts,
changes in LVEDP during stretch were also plotted against %Vinit.
Similar results were observed when plotting the results this way
despite the smaller Vinit of mdx hearts, further accentuating the
increased whole-organ compliance of mdx hearts (Figure 1e). To
visualize the true LV EDP-volume relationship, LVEDP was
plotted against LV volume (Vinit+volume added during stretch
protocol, Figure 1f). Here, mdx hearts initially showed a left-
shifted LVEDP-volume curve compared to WT at lower volumes.
As LV volume was increased, the blunted slope of the LVEDP-LV
volume relationship in mdx hearts approached that of WT hearts
(Figure 1f). Collectively, these results demonstrate the increased
compliance of isolated mdx hearts compared to WT.
Because we have previously shown that LV dimensions are
normalized in mdx mice upon application of membrane sealant
poloxamer 188 in vivo [15], we conducted parallel studies in
isolated hearts perfused with buffer containing P188. Inclusion of
P188 did not affect the increase in LVEDP as volume was added
above Vinit in isolated mdx hearts, suggesting that the alteration in
mechanical compliance we observe are not related to mechanical
instability of the sarcolemma (Figure S1a, b).
To determine if the observed differences in whole-organ
compliance were due to mechanical injury of the heart or to
ischemia caused by high LV pressures, we recorded the flow rate
of perfusate through the coronary vasculature. Throughout the ex
vivo stretch protocol there was no difference in coronary flow
between mdx and WT hearts (Figure S1c). Additionally, to
determine if the observed differences in whole-organ compliance
were due to mechanical injury of mdx hearts during the stretch
protocol, we assessed lactate dehydrogenase (LDH) activity in
perfusates from isolated hearts before and after stretch. WT and
mdx hearts showed similar initial perfusate LDH activity and
showed no increase in perfusate LDH activity following stretch
(Figure S1d). All values for LDH activity recorded for hearts used
in the stretch protocol were less than those recorded following
ischemia/reperfusion injury, suggesting that minimal cell injury or
death occurred during the stretch protocol. Additionally, isolated
hearts recovered cardiac performance to pre-stretch levels
following the ex vivo stretch protocol (Figure 1a, b and Figure
S1e). Collectively, these findings are evidence that the stretch
protocol used in this study causes minimal injury to isolated hearts
and had negligible effects on post-stretch protocol cardiac
function.
To further characterize the effects of altered dystrophin
expression on the mechanical properties of the myocardium,
isolated hearts of mdx carrier females were subjected to the LV
chamber stretch protocol. In these mice, 50% of cardiac myocytes
lack dystrophin due to random X inactivation [37]. Isolated hearts
of mdx carrier females showed whole-organ compliance similar to
WT hearts (Figure 1d, g). We also assessed the whole-organ
compliance of hearts from the dystrophin/utrophin double
knockout (DKO) mouse. Utrophin is a homolog of dystrophin
which is upregulated in mdx mice, compensating for dystrophin
loss and contributing to a relatively mild phenotype compared to
DMD patients [38,39,40]. DKO mice have a severe dystrophic
phenotype which is similar to DMD patients [38,39,40]. DKO
mouse hearts showed increased compliance compared to both WT
and mdx (Figure 1d, h). DKO mice were studied at 4 weeks of age
due to their severe dystrophic phenotype and had smaller LV
volumes (Figure 1c). Because similar volumes were introduced to
all hearts regardless of Vinit, smaller hearts would be predicted to
show greater increases in LVEDP as LV volume is increased Vinit
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32880Figure 1. Response of isolated, contracting dystrophic isolated hearts to ex vivo stretch. A, B) Compressed representative pressure
tracings from WT(A) and mdx (B) hearts during ex vivo stretch protocol. Inset: uncompressed pressure tracings from mdx and WT hearts prior to
stretch, vertical scale bar=50 mmHg, horizontal scale bar=1/7 sec. C) Volume required to reach 8 mmHg EDP within the LV (Vinit). D) Altered whole-
organ compliance of mdx and DKO hearts compared to WT as shown by plotting LVEDP against volume added above Vinit during ex vivo stretch. Mdx
carrier females show normal whole-organ compliance. E) Differences in compliance of mdx and WT hearts are further exaggerated when plotting
%Vinit versus LVEDP. F) Estimation of the true LV volume-EDP relationship based on data from 1C and 1D. Balloon only controls are shown to prove
that recorded changes in pressure were not due to overfilled balloon. G) Whole-organ compliance of isolated WT and mdx carrier female hearts
shown as the LV volume versus LVEDP. H) Whole-organ compliance of isolated mdx and DKO hearts shown as LV volume versus LVEDP. n=5–14. For
C, * - P,0.05 by t-test. For D, * - p,0.05 for C57BL/10SnJ vs. DKO, ‘ -P ,0.05 for C57BL/10SnJ vs. mdx, { -p ,0.05 for mdx versus DKO by two-way
ANOVA with main effects for strain, volume, and an interaction of the two. Values expressed as mean 6 SEM.
doi:10.1371/journal.pone.0032880.g001
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reduced in DKO mice compared to controls despite this smaller
initial volume. The sarcomeric protein titin is a central
determinant of passive compliance in cardiac muscle [41,42].
Alternative splicing of titin early in life may contribute to altered
cardiac compliance as the heart develops [43]. However, in the
mouse, the adult isoforms of titin are predominant after day 5,
suggesting alterations in titin isoform expression did not contribute
to enhanced compliance in DKO hearts [43].
Effects of altering perfusate calcium on mechanical
properties of isolated dystrophic and WT hearts
To determine the effects of altering extracellular calcium
concentrations on the mechanical properties of the myocardium,
isolated hearts were perfused with a modified Kreb’s buffer
containing high (3 mM) calcium or low (1.75 mM) calcium (all
solutions contained 0.5 mM EDTA). Similar to our findings under
standard conditions (2.5 mM calcium+0.5 mM EDTA) isolated
mdx hearts perfused with high and low calcium showed a similar
blunted increase in LVEDP as volume was increased above Vinit as
compared to controls (Figure 2a, b). To further characterize the
effects of altering extracellular calcium on myocardial compliance,
hearts were perfused with buffer lacking calcium and containing
10 mM 2, 3-butanedione monoxime to inhibit excitation-contrac-
tion coupling. Perfusion with this solution halted all contractile
activity of isolated hearts. Non-contracting hearts were then
subjected to mechanical stretch by adding 30 mL to the heart in
1 mL increments as above. Similar to our findings in beating
hearts, non-contracting mdx hearts showed increased whole-organ
compliance compared to WT, as shown by a blunted increase in
LVEDP as LV volume increased (Figure 2c). This is alternatively
quantified in Figure 2d as the volume required to raise LVEDP to
a given value. Statistical analysis by two-way ANOVA showed
significant main effects for strain, volume, and an interaction of the
two, indicating that mdx hearts require significantly greater
volume to raise LVEDP to 60, 80, 100, and 120 mmHg
(Figure 2d). The congruence of our findings in contracting and
non-contracting hearts suggests that, in contrast to individual
myocytes, the altered whole-organ compliance of mdx hearts is not
due to calcium-dependent processes such as sarcomeric contrac-
tion or trans-sarcolemmal influx of extracellular calcium [15].
The use of non-contracting hearts also allowed for quantitative
assessment of end diastolic sarcomere lengths at a set LVEDP.
This analysis is confounded in contracting hearts due to obligatory
contraction-induced changes in sarcomere length. Accordingly, we
measured sarcomere length at a range of set LV pressures to
determine the single-cell manifestations of whole-organ stretch in
non-contracting WT and mdx hearts. Non-contracting hearts
were perfusion-fixed at LVEDP pressures of 8, 80, or 160 mmHg.
Immunofluorescent staining for desmin was then used to visualize
and measure average sarcomere lengths of the mid-LV free wall
(Figure 3a). At each LV pressure tested, mdx and WT hearts had
Figure 2. Response of non-contracting WT and mdx hearts to altered perfusate calcium. A, B) Altered compliance in mdx hearts as shown
by plotting LVEDP against volume added above Vinit during ex vivo stretch when perfused with 2.5 mM (A) or 1.25 mM (B) Ca
2+. C) Increased
compliance in non-contracting hearts perfused with BDM and without calcium during stretch as shown by plotting LVEDP against volume added
above Vinit. D) Quantification of altered compliance in mdx hearts, plotted as volume required to raise LVP from 8 mmHg (Vinit) to 20, 40, 60, 80, 100,
or 120 mmHg. n=5–10. * - p,0.05 by two-way ANOVA with main effects for strain, volume, and an interaction of the two. Values expressed as mean
6 SEM.
doi:10.1371/journal.pone.0032880.g002
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require significantly larger volumes to increase LVP from
8 mmHg to 60, 80, 100, and 120 mmHg (Figure 2d), this suggests
altered stretch at the level of individual myocytes did not
contribute to increased whole-organ compliance in mdx hearts.
Whole-organ heart compliance in other genetic models
of muscular dystrophy
Based on the findings above, we hypothesized that increased
whole-organ compliance observed in mdx hearts is due to
disruption of DGC-mediated connectivity between the extracellu-
lar matrix and the intracellular architecture of the cell. To test this
hypothesis, we determined the whole-organ compliance of other
mouse models of muscular dystrophy in which the DGC or its
binding partners are disrupted: b-sarcoglycan-null mice and dy
2j
mice. b-sarcoglycan is a DGC protein normally expressed in the
heart, the lack of which causes Limb-Girdle Muscular Dystrophy
Type 2E [44,45]. Dy
2j mice carry a mutation in the LAMA2 gene
which causes abnormal splicing of the laminin-a2 transcript and
expression of a truncated protein [46]. The a2 heavy chain subunit
of the extracellular matrix protein laminin is bound by a-
dystroglycan, facilitating the interaction of the DGC with the
extracellular matrix. [47]. Mutations in LAMA2 cause merosin-
deficient muscular dystrophy [48]. Similar to mdx mice, the hearts
of both b-sarcoglycan null and dy
2j hearts showed reduced LV
volumes at normal LVEDP and increased whole-organ compli-
ance compared to WT (C57BL/6) hearts (Figure 4a, b, e). Here,
similar to mdx mice, we observed increased compliance despite
smaller Vinit for b-sarcoglycan null and dy
2j hearts (Figure 4). To
determine if the observed effects on compliance in mdx, dy
2j, and
b-sarcoglycan-null hearts are due to specific effects on the DGC or
other effects of membrane dysfunction in muscular dystrophy, we
also performed the stretch protocol on dysferlin-null hearts.
Dysferlin is a membrane repair protein which is not associated
with the DGC, the lack of which causes Limb Girdle Muscular
Dystrophy Type 2B [49]. These mice have no defect in expression
of DGC proteins [50]. Results showed no differences in LV
volumes or whole-organ compliance of dysferlin-null and WT
control (129S1/SvImJ) hearts (Figure 4c, d, e). Collectively, the
findings of altered whole-organ compliance in b-sarcoglycan null
and dy
2J hearts, but not in dysferlin-null hearts, support the
hypothesis that specific disruption of the cytoskeleton-DGC-
extracellular matrix alters the mechanical properties of the
myocardium and increases whole-organ compliance.
Discussion
The main new finding of this study is that whole-organ
compliance is increased in mdx mice and in other genetic models
of muscular dystrophy involving DGC disruption, but not in a
model of dystrophy caused by defective membrane repair. These
results are evidence that the DGC is an important determinant of
organ-level mechanical compliance in the heart. This, in
conjunction with our findings of similar changes in sarcomere
length despite significantly greater excursions in LV volume lead
us to speculate that side-to-side translation of myocytes past each
other (myocyte slippage) accounts for the increased compliance
observed in mdx, dy
2J and b-sarcoglycan-null hearts.
Numerous studies have shown that loss of dystrophin alters the
response of striated muscle to mechanical stress. In skeletal muscle,
loss of dystrophin alters passive mechanical properties and
increases susceptibility to mechanical injury [51,52,53]. In cardiac
tissue, we and others have previously shown that dystrophin
deficient cardiac myocytes are highly susceptible to mechanical
injury and show increased passive stiffness [14,15,16]. Here, we
have subjected isolated hearts to mechanical distension to
determine the effects of dystrophin loss on whole-organ compli-
ance and susceptibility to mechanical damage. In agreement with
previous findings, we found that mdx hearts show reduced LV
volumes compared to controls (Figure 1c) [15]. In contrast to
individual cardiac myocytes, isolated mdx hearts show increased
compliance compared to normal tissue as LV chamber volume is
increased. This is shown in Figure 1f, with the initially left-shifted
mdx pressure-volume curve approaches controls as LV volume in
increased. This defect is exacerbated in dystrophin/utrophin
double knockout hearts and fully prevented in mdx carrier females
expressing dystrophin in only 50% of cardiac myocytes. During
the distension protocol mdx hearts undergo significant expansion
of the LV with no significant effects on cardiac function,
membrane damage or cell death. Given the stiffness and
Figure 3. Quantification of changes in sarcomere length during whole-organ stretch in non-contracting hearts. A) Representative
image of desmin stained section of fixed heart tissue. Average sarcomere length of circumferentially oriented myocytes from the mid LV free wall was
determined. Scale bar=50 mm. B) Quantitation of average sarcomere length at a range of fixed LV pressures. n=5–10. No significant differences were
detected by two-way ANOVA. Values expressed as mean 6 SEM.
doi:10.1371/journal.pone.0032880.g003
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passive stretch [14,15], this suggests that factors other than
mechanical instability of the membrane contribute to the increased
whole-organ compliance of mdx isolated hearts. This is further
supported by the finding that the altered compliance of mdx hearts
was not corrected by P188. In a previous report, Wilding and
colleagues performed ex vivo stretch and showed no difference
between isolated mdx and WT hearts in LV volumes as LVEDP
was increased up to 30 mmHg [54]. Our findings are in agreement
with this study since we show no significant difference in LVEDP
between mdx and WT as volume is increased within this range
(Figure 1d). However, here we have conducted a more extensive
analysis of the pressure-volume relationship to reveal significant
differences in compliance of mdx hearts compared to WT.
To determine possible mechanisms for the observed changes in
the mechanical properties of isolated hearts, perfusate calcium
concentrations were altered. Increasing, decreasing, or removing
calcium altogether did not alter the enhanced compliance mdx
hearts. This is evidence that neither trans-sarcolemmal calcium
entry through membrane ‘‘micro-tears’’ nor sarcomeric contrac-
tion contributes to the increased compliance of mdx hearts.
However, we cannot exclude that alterations in expression or
activity of other proteins contributes to the increased compliance
observed in dystrophic hearts. For instance, caveolin-3 is
upregulated in mdx mice [55], interacts with the DGC and
numerous cell signaling molecules [56,57], and participates in
buffering mechanical membrane stress [58], and may contribute to
the altered mechanical properties of the mdx myocardium.
Figure 4. Whole-organ passive compliance of isolated hearts from other models of muscular dystrophy. A) Left, altered compliance of
b-sarcoglycan-null and dy
2J hearts as shown by plotting LVEDP against volume added above Vinit during ex vivo stretch. B) Estimation of the true LV
volume-EDP relationship, plotted as in Figure 1F. C) Left, normal compliance of dysferlin-null hearts as shown by plotting LVEDP against volume
added above Vinit during ex vivo stretch. D) Estimation of the true LV volume-EDP relationship. E) Volume required to reach 8 mmHg EDP within the
LV (Vinit). n=5–7. * - p,0.05 for dy
2J versus C57BL/6, ‘ -p ,0.05 for b-sarcoglycan-null versus C57BL/6. Statistical comparisons made by two-way
ANOVA with main effects for strain, volume, and an interaction of the two. Values expressed as mean 6 SEM.
doi:10.1371/journal.pone.0032880.g004
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myocytes in WT and mdx hearts, we determined sarcomere length
at a given LV pressure in non-contracting hearts. Sarcomere
lengths were similar at all LV pressures tested despite the
considerably larger volumes required to alter LV volume in mdx
hearts, suggesting that enhanced stretch of the myocytes does not
account for increased compliance in isolated mdx hearts. Since
alterations in LV volume expansion are not strictly tracked by
proportional changes in sarcomere length, this indicates the
mechanical properties of the dystrophic myocardium are not a
simple extrapolation of findings from isolated cells. To explain
these findings, we propose a model for the accelerated pathological
dilation of the ventricle in DMD where disruption of the DGC
promotes side-to-side myocyte slippage during whole-organ
stretch. A simplified model for this mechanism is shown in
Figure 5. Specifically, we propose that as isolated mdx hearts are
stretched, loss of dystrophin and disruption of the DGC causes
myocytes to translate past each other to a greater degree than
occurs in normal hearts. We speculate that, over time, this
enhanced myocyte slippage contribute to the pathological dilation
of the heart observed in DMD and other forms of inherited
muscular dystrophy which involve disruption of cell-extracellular
matrix linkages. Therefore, in this model, enhanced compliance in
mdx isolated hearts is primarily due to disruptions in the
cytoskeleton-DGC-extracellular matrix axis. Additional experi-
ments showed similarly enhanced compliance in b-sarcoglycan-
null and dy
2J hearts, but not in dysferlin-null hearts, consistent
with our hypothesis that disruption of the DGC-mediated linkage
of cells with the extracellular matrix promotes enhanced whole-
organ cardiac compliance. Collectively, these findings support a
mechanism for the increased whole-organ compliance of mdx
isolated hearts which is independent of sarcolemma instability and
single myocyte compliance. In the broader context of pathophys-
iological processes associated in DMD cardiomyopathy, the
findings presented here suggest a novel mechanism for the
pathological ventricular dilation that occurs in DMD and highlight
the complex physiological interactions that should be considered
when studying diseases at the whole-organ level.
When formulating the working model for the increase
compliance of dystrophic hearts observed here, we have also
considered other possible explanations for our findings. Specifi-
cally, previous reports have shown that chronic ventricular dilation
is associated with alterations in the collagen I/collagen III content,
promoting a more compliant ventricular wall [59,60,61]. Howev-
er, the tight-skin mouse which expresses a ,20% excess of
collagen in the heart show no abnormalities in passive ventricular
compliance [62] and mdx mice typically show no significant
deposition of collagen within the myocardium at the ages tested in
this study [63]. Additionally, the sarcomeric protein titin has
previously been shown to be truncated in skeletal muscle of DMD
patients [42,64,65]. However, our lab has previously shown that
permeabilized cardiac myocytes from the golden retriever
muscular dystrophy dog show no difference in passive compliance
over a wide range of sarcomere lengths [14]. Previous reports have
highlighted the complex arrangement of myocytes in the LV, the
anisotropic mechanical properties of the myocardium, and how
layers of cardiac myocytes may shear past one another during
stretch [66,67,68]. Although our model is consistent with the data
reported, we cannot exclude that the observed increase in
compliance of dystrophic hearts is due to myocardial tissue-level
rearrangement, perhaps through shear along myocardial cleavage
planes, or altered myocyte orientation within the LV. Additionally,
we as show in Figures 1 and 4, the initial LV volumes varied
between strains, with some dystrophic strains showing significantly
smaller LV volumes compared to controls. In this study we have
assumed that the observed differences in LV geometry will not
significantly affect our measurement of compliance.
Although LV dilation is associated with numerous disease
states of the heart, the basis for this pathological change in or-
gan structure is not well understood. Previous studies suggest
that myocyte slippage contributes to LV dilation in numerous
disease states including aortic stenosis, acute and chronic
myocardial infarction, and end-stage dilated cardiomyopathy
[32,69,70,71,72,73]. Specifically, these studies have shown that
pathological dilation of the LV is associated with LV free wall
thinning and reductions in transmural cell number which are not
accounted for by hypertrophy, myocyte lengthening or fibrosis
[32,69,70,71,73]. Ultrastructural analysis of the chronically dilated
LV has shown that pathological LV dilation is associated with
disruption of normal sarcolemmal registry in a dog model of
DCM, suggesting myocyte slippage [72]. These findings, along
with other reports of disrupted DGC expression in cardiomyop-
athy brought on by enteroviral infection [74,75], ischemia [76,77],
acute isoproterenol toxicity [78], or in idiopathic dilated
cardiomyopathy [76,77] lead us to propose that DGC-mediated
changes in whole-heart compliance may be a common pathway to
pathological LV dilation in numerous forms of cardiac disease.
Additionally, the mice used in this study were at an early stage in
the progressive cardiomyopathy of mdx mice and typically show
minimal evidence of histopathology [63]. Therefore, it is possible
that the observed changes in whole-organ compliance in mdx
hearts are an initiating event in the remodeling of the dystrophin
deficient myocardium. Future studies aimed at determining the
age-related changes in cardiac compliance of mdx mice may be
useful for understanding the progression of cardiomyopathy in
DMD.
With regard to the relevance of the findings presented here to
the pathogenesis of heart disease in DMD, there are limitations of
this study that need to be considered. The retrograde perfused
isolated heart preparation used in this study is a well-established
and widely used technique for assessing whole-organ cardiac
function as measured during isovolumic contraction and relaxa-
tion [79,80]. However, this technique does not faithfully
recapitulate the mechanical rigors of contraction and relaxation
due to lack of physiological loading conditions [80]. Previous
reports have shown that cardiac function of the dystrophin
deficient heart suffers greatly under conditions of physiological
loading, due to mechanical instability of the membrane [81,82].
Although this is certainly a limitation of this study, the absence of
physiological loading allowed us to isolate and study mechanical
properties of the intact dystrophin deficient heart independent of
myocardial damage caused by physiological loading conditions. A
significant body of evidence suggests that sarcolemmal instability is
the primary cellular defect caused by loss of dystrophin and plays a
significant role in pathological remodeling of the heart in DMD
[14,15,16]. However, we assert that, in addition to the well-
established effects of myocyte damage and loss due to mechanical
instability of the membrane, the dystrophin deficient heart exhibits
a heightened propensity to undergo myocyte slippage which
contributes to the progressive pathological dilation of the ventricle
in DMD. In addition to this limitation, when using our ex vivo
stretch protocol we observed differences in whole-organ compli-
ance between WT and mdx hearts at LVEDP well above the
normal physiological range. We speculate that the processes
resulting in increased compliance in isolated hearts at high
LVEDP may also occur under normal conditions in vivo, but at a
much slower rate. This is in line with the slowly progressive
dilation that occurs over the course of years in DMD [26,27].
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agreement with previous findings showing that while the sarcomeric
filament and disregulgated calcium handling influences the mechanical
properties of the myocardium at lower sarcomere lengths, extracellular
matrix proteins contribute significantly at higher sarcomere lengths
[15,83,84]. Increased compliance in dystrophic hearts was only seen at
increased sarcomere lengths, suggesting that these defects were cause
by altered extracellular matrix interactions.
In addition to our findings in mdx hearts, we also found similar
disturbances in the whole-organ mechanical properties of b-
sarcoglycan-null and dy
2J hearts. Mutations in b-sarcoglycan and
laminin-a2 cause muscular dystrophy and, importantly, dilated
cardiomyopathy [46,85,86,87,88]. However, there is evidence
from previous studies in skeletal muscle to suggest divergence in
the mechanisms by which these mutations cause disease when
compared to mdx mice. b-sarcoglycan-null mice show muscle
wasting and increased membrane permeability [85]. It is not
known if b-sarcoglycan-null mice show enhanced susceptibility to
contraction-induced injury, but previous studies have shown
significant divergence in susceptibility to contraction-induced
injury in genetic models of sarcoglycan deficiency [89,90,91].
Dy
2J mice show muscle wasting, but no evidence of membrane
permeability or susceptibility to contraction-induced injury
[92,93]. Expression of the anti-apoptotic protein BCL2 corrects
muscle defects in laminin deficient mice, but not mdx mice,
suggesting that aberrant apoptosis plays a role in the pathology of
these mice [94]. Despite these differences in the mechanisms of
muscle wasting in mdx, dy
2J, and b-sarcoglycan-null mice, each of
these models shows enhanced whole-heart compliance. We
speculate that these mouse models share the phenotype of
increased whole-heart compliance due to disruptions of cell-
extracellular matrix interactions. Genetic ablation of b-sarcogly-
can weakens the interaction of a-dystroglycan with the DGC [88]
and the mutant laminin-a2 heavy chain expressed by dy
2J mice is
defective in its ability to form stable polymers [95], suggesting
mechanisms for the disruption of the contacts between myocytes
and the basement membrane. Collectively, the finding of altered
mechanical properties in the hearts of mdx, b-sarcoglycan-null
and dy
2J mice are evidence that altering cell-extracellular matrix
contacts is a common mechanism for pathological dilation of the
heart in diseases which alter cell-extracellular matrix interactions
by a variety of different mechanisms. The lack of mechanical
defects in the hearts of dysferlin-null mice further supports this
hypothesis. Mutations in dysferlin cause muscular dystrophy, but
development of dilated cardiomyopathy is rare [96,97]. Since
dysferlin is not known to directly participate in cell-cell or cell-
matrix contacts, the finding of normal compliance in dysferlin-null
hearts supports the hypothesis that changes in whole-organ
mechanical compliance are specifically caused by disruptions in
the cell-extracellular matrix axis of connectivity. The findings
presented in this study may therefore have relevance for other
disease processes which involve pathological cardiac dilation.
Materials and Methods
Mice
C57BL/10SnJ (000666), C57BL/10ScSnJ-DMD
mdx/J (001801),
129-Dysf
tm1Kcam/J (006830), 129S1/SvImJ (002448), B6.WK-La-
Figure 5. Simplified model for the mechanical properties of the dystrophic myocardium. Top, model for the increased stiffness of mdx
myocytes. Stretch causes membrane permeability and influx of extracellular calcium, leading to unregulated contraction (indicated in red). Bottom,
simplified model for the effects of dystrophin expression on myocardial compliance. In mdx hearts, membrane permeability may initially cause
contraction of LV volume at normal LVEDP, resulting in a left shift in the LV volume-EDP curve. As volume is increased, loss of dystrophin leads to
increased slippage of myocytes past one another, leading to increased compliance. This is corrected by expression of dystrophin in 50% of myocytes
in mdx carrier females.
doi:10.1371/journal.pone.0032880.g005
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dy-2J/J (000524), B6.129-Sgcb
tm1Kcam/1J (006832) were purchased
from the Jackson Labs (Bar Harbor, Maine). Mdx carrier females
were created by breeding C57BL/10SnJ and C57BL/10ScSnJ-
DMD
mdx/J mice. Dystrophin-utrophin double knockout (DKO)
mice were a kind gift from Dr. Dawn Lowe at the University of
Minnesota [39]. Mice were used at 8–10 weeks of age, with the
exception of DKO mice, which were used at 4 weeks due to their
severely shortened lifespan.
Isolated heart preparation
Mice were anaesthetized with sodium pentobarbital and hearts
removed via thoracotomy. Hearts were then immediately placed
in ice cold modified Krebs-Henseleit buffer (118 mM NaCl,
4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4,1 0 m M
glucose, 25 mM NaHCO3, 2.5 mM CaCl2, 0.5 mM EDTA,
2 mM sodium pyruvate) while the aorta was isolated and
cannulated. Hearts were then retrograde-perfused through with
warm buffer bubbled with 95% O2 and 5% CO2 to maintain a pH
of 7.4. For experiments in non-contracting hearts, isolated hearts
were perfused with a similar buffer lacking calcium and including
the contractile inhibitor 10 mM 2,3–butanedione monoxime
(BDM).The left atrium was then removed and a plastic balloon
was inserted into the LV. An in-line pressure transducer allowed
for the recording of pressures within the LV. To assess the
mechanical compliance of isolated hearts, balloons were inflated to
a physiological left ventricular end diastolic pressure (LVEDP) of
8 mmHg. Volume required to bring LVEDP to this normal range
was recorded as Vinit.
Ex vivo stretch protocol
To mechanically stretch isolated hearts, volume was added in
1 mL increments. For contracting hearts, 15 mL was added above
Vinit. For non-contracting hearts, 30 mL was added above Vinit.I n
both contracting and non-contracting hearts, the ex vivo stretch
protocol was performed twice: once to condition the heart and a
second time to record functional data. All data reported in this
study was taken from the second run through the stretch protocol.
Additionally, for this study it was necessary to create balloons with
significantly larger volumes than the murine LV to ensure that
pressure developed in the balloon was due to pressure against the
LV wall and not against the balloon itself.
Determination of sarcomere length
To determine sarcomere length at given LV pressures, balloons
were inflated and clamped to hold LVP at 8, 80 or 160 mmHg in
non-contracting hearts, which were then perfused with 10% zinc-
formallin and fixed overnight at 4 degrees Celsius. The following
day, the LV free wall was dissected, cut transversely at the mid-
wall and embedded in paraffin. Serial 5 mm sections were then cut
and mounted on histological slides. Immunofluorescence for the Z-
disk intermediate filament desmin was then performed to visualize
sarcomere length. In brief, sections were dewaxed and rehydrated
and blocked with 20% normal goat serum for 1 hour at room
temperature. Rabbit anti-desmin primary antibody (Novus
Biologicals, NB120-15200) was applied at a 1:300 dilution for
1 hour at room temperature. After washing, goat anti-rabbit IgG-
AlexaFluor 594 (Molecular Probes, A-11037) was applied for
1 hour at room temperature. Sections were then washed and
mounted with Vectashield for visualization. Slides were visualized
using a Zeiss LSM510 META confocal microscope (Carl Zeiss).
Lactate dehydrogenase activity assay
Perfusates were collected from isolated hearts immediately
before or after the ex vivo stretch protocol and immediately frozen
in liquid nitrogen. 5 mL of perfusate was then added to 200 mLo f
solution containing 0.12 mM NADH, 2.3 mM pyruvate, and
0.035% BSA in 100 mM sodium phosphate pH=7.5. Absorbance
at 340 nm was then measured in a plate reader (FLUOstar
Omega, BMG Labtech) at 1 minute intervals for 15 minutes at a
constant temperature of 37 degrees Celsius.
Statistics
Comparisons between more than 2 groups were made by one-
way analysis of variance with a Tukey post-test. When more than
one independent variable was tested, two-way analysis of variance
with a Bonferroni post-test was used to compare groups. All
statistical analysis was carried out using Prism (GraphPad
Software).
Supporting Information
Figure S1 P188 does not affect whole-organ compliance
and ex vivo stretch does not cause ischemia or impair
cardiac function. A) Whole-organ compliance of isolated mdx
hearts with and without poloxamer 188 in the perfusate (mdx data
is same data used in Figure 1). B) Vinit of mdx perfused with and
without poloxamer 188 perfusate (mdx data is same data used in
Figure 1). C) Rate of perfusate flow through the coronary
vasculature in mdx and WT hearts during ex vivo stretch protocol.
D) LDH activity in perfusates from WT and mdx hearts taken
before and after ex vivo stretch protocol. E) Comparison of LVDP
before and after ex vivo stretch protocol. No significant differences
between observed between WT and mdx mice by two-way
ANOVA. For A, B, n=7–14. For C, n=11–14. For D, n=5–9.
For E, n=8–12.* - p,0.05 vs. all other groups by one-way
ANOVA. Values expressed as mean 6 SEM.
(TIF)
Table S1 Baseline ex vivo functional data for isolated
WT and mdx hearts. Contractile function as shown by LV
developed pressure (LVDP) and the maximum derivatives of LV
pressure (dP/dt max.) were similar between groups. Lusitropic
function as measured by LV end diastolic pressure (LVEDP) and
the minimum derivative of LV pressure (dP/dt min.) were also
similar between the groups by student’s t-test. n=12–15. Values
expressed as mean 6 SEM.
(TIF)
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